Ocugen, Inc. stock: filings, catalysts and timeline

1. Filed

2. Thu 15 Oct · 8-K

   8-K filed 2026-10-15

   Gap Very high · 50 → Very high · 79

   Progress is running ahead of attention.

3. Thu 15 Oct · 8-K

   8-K · Items 1.01, 8.01 — Material agreement

   Ocugen entered an exclusive license agreement with Roots Pharmaceutical for OCU400 (modifier gene therapy for retinitis pigmentosa) in the Middle East and North Africa. Deal includes upfront fee, up to $4M in development milestones, up to $255M in sales milestones, and 22% royalties on net sales.

   Gap Very high · 50 → Very high · 79

   Progress is running ahead of attention.

4. Tue 6 Oct · 8-K

   8-K filed 2026-10-06

5. Wed 23 Sep · 8-K

   8-K filed 2026-09-23

   Gap Very high · 52 → Very high · 49

   The gap narrowed — attention is catching up.

6. Tue 8 Sep · 8-K

   8-K · Item 8.01 — Other events

7. Thu 6 Aug · 8-K

   8-K · Item 2.02 — Results of operations

8. Thu 6 Aug · 10-Q

   Quarterly report (10-Q), period ending 31 Jul 2026

9. Mon 13 Jul · 8-K

   8-K · Item 8.01 — Other events

10. Thu 11 Jun · 8-K

    8-K · Item 8.01 — Other events

11. Wed 3 Jun · 8-K

    8-K · Item 5.02 — Director or officer change

12. Thu 14 May · 8-K

    8-K · Items 5.02, 8.01 — Director or officer change

13. Thu 14 May · 8-K

    8-K · Items 2.03, 3.02 — New financial obligation

14. Fri 8 May · 10-Q

    Quarterly report (10-Q), period ending 30 Apr 2026

15. Thu 7 May · 8-K

    8-K · Items 1.01, 1.02, 2.02, 2.03, 3.02 — Material agreement

16. Tue 5 May · 8-K

    8-K · Items 2.02, 8.01 — Results of operations

17. Mon 4 May · 8-K

    8-K · Items 2.02, 8.01 — Results of operations

18. Fri 27 Mar · 8-K

    8-K filed 2026-03-27

19. Tue 24 Mar · 8-K

    8-K filed 2026-03-24

20. Fri 20 Mar · 8-K

    8-K · Item 8.01 — Other events

21. Wed 4 Mar · 10-K

    Annual report (10-K), FY2026

22. Wed 4 Mar · 8-K

    8-K · Item 8.01 — Other events

23. Wed 4 Mar · 8-K

    8-K · Item 2.02 — Results of operations

24. Mon 9 Feb · 8-K

    8-K · Item 5.02 — Director or officer change

25. Fri 23 Jan · 8-K

    8-K · Item 8.01 — Other events

26. Wed 21 Jan · 8-K

    8-K · Items 1.01, 8.01 — Material agreement

27. Thu 15 Jan · 8-K

    8-K · Item 8.01 — Other events

28. Thu 18 Dec · 8-K

    8-K · Item 5.02 — Director or officer change

29. Wed 5 Nov · 8-K

    8-K · Item 2.02 — Results of operations

30. Wed 5 Nov · 10-Q

    Quarterly report (10-Q), period ending 31 Oct 2025

31. Thu 18 Sep · 8-K

    8-K · Item 1.02 — Material agreement terminated

32. Tue 16 Sep · 8-K

    8-K · Item 1.01 — Material agreement

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.